drugset
Drugs / Daratumumab and hyaluronidase-fihj
last change 10 days ago re-read 3 minutes ago

Daratumumab and hyaluronidase-fihj

Developed for
monoclonal gammopathy of uncertain significance · peripheral neuropathy
Investigated by
Georgetown University · Janssen, LP

Trials 1

today NCT06046287 · Ph 2
2026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06046287 Sep 2025 monoclonal gammopathy of uncertain significance, peripheral neuropathy Georgetown University Withdrawn No outcome recorded Stop: Enrollment

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2026-04-29 Janssen Research & Development, LLC Results Johnson & Johnson ushers in the next wave of innovation in cancer care with more than 20 clinical and real-world studies at ASCO 2026 jnj.com ↗
Subgroup analysis from the Phase 3 PERSEUS study evaluating the benefit ofDARZALEXFASPRO®(daratumumab and hyaluronidase-fihj) in transplant-eligible patients with high- and standard-risk multiple myeloma (Oral Abstract #7505)
2023-06-03 Janssen Research & Development, LLC Results Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma jnj.com ↗
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX FASPRO® combination biweekly regimen showed an overall response rate of more than 80 percent
2022-06-10 Janssen Research & Development, LLC Results Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma jnj.com ↗
Results from the study show heavily pretreated patients with multiple myeloma treated with the combination, including talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W), achieved high rates of responses, including for patients refractory to anti-CD38 treatment.

All press releases naming this drug 33 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Daratumumab and hyaluronidase-fihj ClinicalTrials.gov intervention name — accepted as the source's own label NCT06046287 ↗
Route Subcutaneous “subucatneous” NCT06046287 ↗